Recently launched Syndesi Therapeutics SA is developing novel treatments for neurodegenerative diseases based on a worldwide license from UCB SA to develop and commercialize a series of pro-cognitive synaptic vesicle protein modulators.
Syndesi will build on the legacy of work by UCB to further develop novel SV2A modulators that have the potential...








